REHOVOT, Israel--(BUSINESS WIRE)--July 11, 2006--Kamada (TASE:KMDA), a bio-pharmaceutical developer and manufacturer of prescription drugs, has been granted by the European Agency for the Evaluation of Medicinal Products (the EMEA), approval of its plan to begin phase 1 clinical trials on a respiratory form of its API drug product. Successful results of the clinical trials of the respiratory form will mark a breakthrough in the treatment of Congenital Emphysema, as well as other lung disease indications.
